Cg Oncology Inc [CGON] stock is trading at $26.28, up 0.15%. An important factor to consider is whether the stock is rising or falling in short-term value. The CGON shares have gain 0.38% over the last week, with a monthly amount glided 5.71%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cg Oncology Inc [NASDAQ: CGON] stock has seen the most recent analyst activity on May 02, 2025, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $41. Previously, Scotiabank started tracking the stock with Sector Perform rating on April 16, 2025, and set its price target to $23. On January 07, 2025, TD Cowen initiated with a Buy rating. UBS started tracking the stock assigning a Buy rating and suggested a price target of $60 on October 24, 2024. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $66 as its price target on September 23, 2024. ROTH MKM started tracking with a Buy rating for this stock on August 28, 2024, and assigned it a price target of $65. In a note dated June 28, 2024, BofA Securities initiated an Buy rating and provided a target price of $65 on this stock.
Cg Oncology Inc [CGON] stock has fluctuated between $14.80 and $40.47 over the past year. Currently, Wall Street analysts expect the stock to reach $55 within the next 12 months. Cg Oncology Inc [NASDAQ: CGON] shares were valued at $26.28 at the most recent close of the market. An investor can expect a potential return of 109.28% based on the average CGON price forecast.
Analyzing the CGON fundamentals
Cg Oncology Inc [NASDAQ:CGON] reported sales of 0.66M for the trailing twelve months, which represents a drop of -90.17%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -203.02%, Pretax Profit Margin comes in at -159.45%, and Net Profit Margin reading is -159.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.17 and Total Capital is -0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.77 points at the first support level, and at 25.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.58, and for the 2nd resistance point, it is at 26.89.
Ratios To Look Out For
For context, Cg Oncology Inc’s Current Ratio is 30.97. On the other hand, the Quick Ratio is 30.97, and the Cash Ratio is 1.83. Considering the valuation of this stock, the price to sales ratio is 3035.15, the price to book ratio is 2.84.
Transactions by insiders
Recent insider trading involved POST LEONARD E, Director, that happened on May 21 ’25 when 1000.0 shares were sold. Director, POST LEONARD E completed a deal on Apr 28 ’25 to sell 1000.0 shares. Meanwhile, Director POST LEONARD E sold 1000.0 shares on Mar 17 ’25.
